All In Biotech

Drug Trial Radar · NCT06137144

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

161

Planned (sponsor's estimate)

Start

Jan 23, 2024

Primary completion

May 3, 2029

Study completion May 3, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

Conditions

  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Peripheral T-cell Lymphoma (PTCL)
  • PTCL-NOS
  • ALCL
  • AITL

Interventions

  • AZD3470Drug

    AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.

  • PembrolizumabDrug

    Pembrolizumab (CAS nr: 1374853-91-4 )

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: From Screening continuously until 28 days after the last dose of study medication.
  2. Incidence of DLTs (Dose Escalation Cohorts only)Time frame: From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days).

Locations

38 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Withdrawn

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Adelaide, Australia · Withdrawn

  • Research Site

    Birtinya, Australia · Withdrawn

  • Research Site

    Fitzroy, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    South Brisbane, Australia · Withdrawn

  • Research Site

    Waratah, Australia · Withdrawn

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Créteil, France · Terminated

  • Research Site

    Dijon, France · Recruiting

  • Research Site

    Lille, France · Recruiting

  • Research Site

    Pierre-Bénite, France · Recruiting

  • Research Site

    Villejuif, France · Recruiting

  • Research Site

    Berlin, Germany · Not yet recruiting

  • Research Site

    Cologne, Germany · Recruiting

  • Research Site

    Erlangen, Germany · Not yet recruiting

  • Research Site

    Würzburg, Germany · Recruiting

  • Research Site

    Alessandria, Italy · Recruiting

  • Research Site

    Bologna, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Bunkyō City, Japan · Recruiting

  • Research Site

    Kōtoku, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    L'Hospitalet de Llobregat, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Manchester, United Kingdom · Recruiting

  • Research Site

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.